Faron, etusivu

releases and publications

Final Patient Identified for the BEXMAB Study

Faron’s Financial Calendar for 2025

Regulatory

Faron presents BEXMAB data at ASH Annual Meeting

Interactions with UK Regulatory Authorities

Positive Phase 2 Interim Results from BEXMAB Trial

Regulatory

Targeting Soluble Clever-1 for Autoimmune Diseases

Shareholders’ Nomination Board

Regulatory

Faron’s Capital Markets Day 2024

Regulatory

Faron announces Capital Markets Day

Grant of options

Insider Transaction Regulatory
Next
Back to top